期刊
GASTROENTEROLOGY
卷 156, 期 2, 页码 325-337出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2018.10.032
关键词
Drug; HBsAg; Vaccine; Inflammation
资金
- German Research Foundation (DFG) through the collaborative research center TRR36
- German Research Foundation (DFG) through the collaborative research center TRR179
- EU H2020 grant Hep-CAR
- German Ministry of Education and Research (BMBF) via a KMU Innovativ project StabVac B
- German Center for Infection Research (DZIF)
- Helmholtz Association
- [PR 618/7]
Fewer than 1% of chronic hepatitis B virus infections per year are cured with antiviral treatment. This creates a need for long-term treatment, which poses challenges for patients and health systems. Because cure is accompanied by recovery of antiviral immunity, a combination of direct-acting antiviral agents and immunotherapy are likely to be required. Extensive efforts have been made to identify determinants of the failed immune response to hepatitis B virus in patients with chronic infection. We review mechanisms of immune dysfunction in patients with chronic hepatitis B virus infection, immunotherapy strategies in development, and the challenges associated with successful implementation of immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据